Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026)
Scynexis' (SCYX) quarterly Net Income towards Common Stockholders came in at -$7.1 million in Q2 2026, down 2.98% on a YoY basis from -$7.3 million in Q2 2025, and up 56.78% quarter-over-quarter from -$16.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$7.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 2.98% year-over-year to -$7.1 million; the trailing twelve-month figure through Jun 2026 stood at -$18.0 million (down 20.73% YoY), and the FY2025 full-year result was -$6.8 million, up 59.26% from the prior year.
- Net Income towards Common Stockholders improved to -$7.1 million in Q2 2026 per SCYX's latest filing, from -$16.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $122.3 million in Q2 2023 and bottomed at -$33.9 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$2.7 million across 5 years, with a median of -$6.4 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 4789.92% in 2022, then surged 8857.96% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$6.0 million in 2022, then slumped by 463.33% to -$33.5 million in 2023, then surged by 100.47% to $157000.0 in 2024, then soared by 8857.96% to $14.1 million in 2025, then plunged by 150.41% to -$7.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.1 million, -$16.4 million, and $14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -7.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Mn |
| Mar 31, 2026 | -16.40 Mn |
| Dec 31, 2025 | 14.06 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -33.54 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -5.95 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -24.60 Mn |
| Sep 30, 2021 | -605,000.00 |